Anonymous User
Login / Registration

a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2021; 75(6): 545–549. doi: 10.48095/ccgh2021545.

Effect of ursodeoxycholic acid in postcholecystectomy cholestatic hepatopathy verified by ultrasonography

Katarína Demková1, Tibor Varga ml.2, Ján Tokarčík1, Maroš Rudnay3, Dominik Šafčák4

+ Affiliation


Cholestasis syndrome is accompanied by a large number of diverse liver and biliary tract diseases. Many cholestatic changes are fully reversible in the first phase. However, with long-term cholestasis, extensive hepatocyte dysfunction occurs, the disease progresses, and many cholestatic syndromes result in irreversible liver damage and failure. Cholestatic liver diseases represent an important group of liver diseases that are an indication for liver transplantation. Postcholecystectomy syndrome is an imprecisely defined term, which includes a set of ongoing or recurrent or new difficulties of patients after gallbladder surgery. We distinguish between early postcholecystectomy syndrome immediately in the postoperative period, or late postcholecystectomy syndrome, which occurs months or even years later. Ultrasonography is the first imaging examination method for diseases of the liver and hepatobiliary system. It is a non-invasive method, available, relatively cheap, easily repeatable, and it does not represent a burden for the patient. Common bile duct dilatation after cholecystectomy is a common accidental finding that is inconclusive in the absence of clinical symptomatology and with normal laboratory findings. Ursodeoxycholic acid forms the basis of cholestasis therapy, the only treatment whose efficacy in cholestatic liver disease has been demonstrated in randomized and long-term studies. A further positive is that many years of ursodeoxycholic acid administration are not accompanied by more serious side effects. This case report supports the concept of a prompt and at the same time deepening beneficial effect of ursodeoxycholic acid treatment in patients with cholestatic hepatopathy verified by ultrasonography indicated for conservative treatment or refusing invasive treatment.


cholestáza, postcholecystektomický syndrom, ultrasonography, ursodeoxycholic acid

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users


1. Hůlek P, Urbánek P et al. Hepatologie. 3. vyd. Praha: Grada Publishing 2018.
2. Lukáš K et al. Gastroenterologie a hepatologie pro zdravotní sestry. 1. vyd. Praha: Grada Pub­lishing 2005.
3. Klener P et al. Vnitřní lékařství. 4. vyd. Praha: Galén 2011.
4. Hrušovský Š. Praktická hepatológia. 3. vyd. Bratislava: HERBA 2015.
5. Češka R et al. Interna. 3. vyd. Praha: Triton 2020.
6. Yu MH, Kim YJ, Park HS et al. Benign gallbladder diseases: imaging techniques and tips for differentiating with malignant gallbladder diseases. World J Gastroenterol 2020; 26(22): 2967–2986. doi: 10.3748/wjg.v26.i22.2967.
7. Bo X, Chen E, Wang J et al. Dia­gnostic accuracy of imaging modalities in differentiating xanthogranulomatous cholecystitis from gallbladder cancer. Ann Transl Med 2019; 7(22): 627. doi: 10.21037/atm.2019.11.35.
8. Horák J, Ehrmann J. Hepatologie do kapsy. 1. vyd. Praha: Mladá fronta 2014.
9. Ratanaprasatporn L, Uyeda JW, Wortman JR et al. Multimodality imaging, including dual-energy CT, in the evaluation of gallbladder disease. Radiographics 2018; 38(1): 75–89. doi: 10.1148/rg.2018170076.
10. Catalano OA, Sahani DV, Kalva SP et al. MR imaging of the gallbladder: a pictorial essay. Radiographics 2008; 28(1): 135–155. doi: 10.1148/rg.281065183.
11. Niehaus J. Sonografie praktická příručka. 1. vyd. Praha: Grada Publishing 2020.
12. Križanová M et al. Farmakológia. Martin: Osveta 2005.
13. Juřica J. Ursodeoxycholová kyselina. Gastroent Hepatol 2016; 70(5): 457–462. doi: 10.14735/amgh2016457.
14. Marek J et al. Farmakoterapie vnitřních nemocí. 4. vyd. Praha: Grada Publishing 2010.

Credited self-teaching test